沃森生物(300142.SZ):中保嘉沃及其一致行動人擬合計減持不超1691.18萬股
格隆匯11月6日丨沃森生物(300142.SZ)公佈,持有公司股份約7687.19萬股(佔公司總股本比例5.00%)的股東嘉興裕保投資合夥企業(有限合夥)-無錫中保嘉沃投資合夥企業(有限合夥)(“中保嘉沃”)及其一致行動人中投保信裕資產管理(北京)有限公司-中投保信裕梧桐9號私募投資基金(持有公司股份1537.43萬股,佔公司總股本比例1.00%,“梧桐9號基金”)計劃自減持股份的預披露公告披露之日起15個交易日後的6個月內以集中競價交易方式和大宗交易方式減持公司股份不超過約1691.18萬股(佔公司現有總股本的比例不超過1.10%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.